Cisplatin (Synonyms: CDDP)

Cell lines

H69 SCLC cells

Reaction Conditions

H69 SCLC cells were treated with100 ng/ml cisplatin, to produce the H69-CP or 200 ng/ml cisplatin to obtain the H69CIS200 cells. These doses are below an IC50 for cisplatin and are within the range achieved in the clinical use of cisplatin.

Applications

The cells were 2- to 4-fold resistant to cisplatin, which could be used to further study the resistance mechanism.

Animal models

Adult male Wistar rats, weighing 160-200 g

Preparation Method

The rats were kept at 25 °C on a 12/12 h light/dark cycle, in single plastic cages with bedding, with access to standard rat food and water ad libitum. Rats were randomly assigned to one of three groups: 1) Control group, who received no intervention and maintained a regular diet; 2) Gentamicin group, who were administered 100 mg/kg BW IP gentamicin daily for 7 days; 3) Cisplatin group, who were administered 1.5 mg/kg BW IP cisplatin twice a week for 3 weeks.

Dosage form

1.5 mg/kg

Applications

Cisplatin and gentamicin could significantly elevate serum levels of creatinine, uric acid, and urea, with cisplatin showing higher elevation. Cisplatin could also significantly decrease the GSH and GPx levels.

References:

[1]. Stordal B, et al. Understanding cisplatin resistance using cellular models. IUBMB Life. 2007 Nov;59(11):696-9.

[2]. Abouzed TK, et al. Assessment of gentamicin and cisplatin-induced kidney damage mediated via necrotic and apoptosis genes in albino rats. BMC Vet Res. 2021 Nov 16;17(1):350.